Newborn screening (NBS) involves the collection of blood from the heel of a newborn baby and testing it for a list of rare and inheritable disorders. New biochemical screening technologies led to expansions of NBS programs in the first decade of the 21st century. It is expected that they will in time be replaced by genetic sequencing technologies. These developments have raised a lot of ethical debate. We reviewed the ethical literature on NBS, analyzed the issues and values that emerged, and paid particular interest to the type of impacts authors think NBS should have on the lives of children and their families. Our review shows that most authors keep their ethical reflection confined to policy decisions, about for instance (a) the purpose of the program, and (b) its voluntary or mandatory nature. While some authors show appreciation of how NBS information empowers parents to care for their (diseased) children, most authors consider these aspects to be 'private' and leave their evaluation up to parents themselves. While this division of moral labor fits with the liberal conviction to leave individuals free to decide how they want to live their private lives, it also silences the ethical debate about these issues. Given the present and future capacity of NBS to offer an abundance of health-related information, we argue that there is good reason to develop a more substantive perspective to whether and how NBS can contribute to parents' good care for children. -have, however, famously argued in the past that it is impossible to make policy that remains neutral about the good life. 5 In line with their way of thinking, we argue here that the envisioned future development of NBS programs make it important to discuss whether and how NBS should be allowed to influence caring relationships within the family. In Table 4 we suggest questions that provide a starting point to that debate.
1 NBS programs evolved from a biochemical success story: they started from 1963 onwards, when American biochemist Robert Guthrie developed a blood test for phenylketonuria (PKU) . PKU is a rare metabolic disease which-if left untreated-results in severe physical and mental retardation. Detection of PKU right after birth, coupled with a strict diet that avoids phenylalanine in food, largely prevented the detrimental effects of the disease. Given this health improvement, and the forceful lobby of pediatricians and parents of PKU-affected children, many countries in Europe, the Americas, Australia, and Asia started screening all newborn children for PKU. In our article we focus on blood-based NBS of noninfectious disorders. We exclude all other types of screening performed on newborns, such as a hearing test or pulse oximetry.
availability of tandem mass spectrometry, which allows for the detection of over 60 diseases with a single test based on biochemical components of blood. As almost all diseases included in NBS-except for example congenital hypothyroidism, which many programs target-are genetic in nature, it is expected that these biochemical technologies used for screening will be replaced by next generation sequencing (NGS) technologies within 5-10 years, making it possible to disclose an abundance of health-related information at birth. 4 These developments have raised a lot of ethical debate. In this article we reviewed this ethical debate on NBS and analyzed the issues and values that emerge. The results of this analysis are presented in Sections 2 and 3 of this article as well as in Table 3 . Our analysis will show, however, that the current debate about ethics of NBS has limitations, which can be explained on the basis of its tacit liberal presuppositions regarding what are and what are not appropriate topics for debate in policy-making, including policy about NBS. Consequently, issues about whether and how NBS can help parents to care well for their children are largely ignored, as liberalism prescribes policymakers to refrain from influencing the way in which people choose to lead their private lives including how they raise and care for their children. Many ethicists-especially communitarians and care ethicists -have, however, famously argued in the past that it is impossible to make policy that remains neutral about the good life. 5 In line with their way of thinking, we argue here that the envisioned future development of NBS programs make it important to discuss whether and how NBS should be allowed to influence caring relationships within the family. In Table 4 we suggest questions that provide a starting point to that debate.
| M E TH ODS
In this paper, we aimed to review the issues covered in ethical debates on NBS. By combining search terms related to these two elements (ethics and NBS), we searched for English language articles published between January 1, 2001 and July 1, 2016 in PubMed. Technologies able to detect many diseases with a single test were introduced in NBS programs starting in 2001, hence the chosen time period.
We screened the titles and abstracts of all articles identified for their eligibility. For inclusion, each paper had to (a) concern NBS for inherited diseases during the first weeks of life, making use of blood withdrawal, (b) contain discussion of ethical issues, and (c) be nonempirical in nature (i.e., theoretical, analytical, argumentative, opinionating, commentaries, conceptual, or review articles). When inclusion or exclusion could not be decided on the basis of title and abstract, we retained and reviewed a full-text copy.
Our initial search identified 336 records. Based on title and abstract, 193 could be excluded. The remaining 143 papers were read in full. A further 42 were excluded because they were unavailable,
were not about NBS, did not contain any discussion of ethical issues, and/or were solely empirical in nature.
After this selection, 101 articles remained. We reviewed the content of these articles, and ordered the issues and questions in themes and subthemes, presented in Tables 1-3 . A full search strategy containing the search terms used as well as a complete record of the reasons for exclusion at each step of the process is available upon request. 
Risk information
Risk information does not provide the benefit of certainty, but reveals a probability that a person will develop a diseasesuch as breast or colon cancer, or diabetes-later in life. Sometimes interventions are available to prevent or decrease the probability of the disease occurring; sometimes no such measures are available.
Carrier status information Carrier status (CS) information is not beneficial to the health of the infant; it will only become (potentially) relevant to the child when it reaches reproductive age. CS information may be a by-product of screening with biochemical technologies such as tandem mass spectrometry or high-performance liquid chromatography. However, if WGS will be used to conduct NBS in the future, it will likely lead to the identification of a greater number of carriers of different conditions.
Disease information that is difficult to classify Some disease information may be difficult to classify in any of the above categories. Duchenne Muscular Dystrophy, for example, is a serious late(r)-onset disease in boys for it reveals its first symptoms at age 4-5. Girls are only carriers and 80-90% of girls will remain asymptomatic. Lysosomal storage disorders may produce symptoms later in childhood, but patients may also remain symptom-free until they are middle-aged. Pompe disease has earlier-and later-onset variants. Including these diseases means that NBS will produce different types of information for different people and some people would receive a diagnosis long before there are symptoms-if symptoms occur at all. In addition to these two themes, issues related to the justification of storage, governance, ownership and use of residual bloodspots after NBS also feature in the ethical literature on NBS. While relationships play a role here too, we chose to exclude this theme here because it is not exclusively discussed in the ethical literature about NBS, since residual blood may also be retained and stored after regular diagnoses or research and a presentation of the ethical issues raised about storage in the NBS literature would therefore be incomplete. Historical studies support this criticism of the scientific justification for NBS. They describe that little was known even about PKU when national PKU screening programs were initially launched; mildly and more seriously affected children were treated in the same way, thus producing cognitive deficits in patients who were overtreated (Paul, op. cit. note 14; Mitchell, M. X. (2017) . Screening out controversy: Human genetics, emerging techniques of diagnosis, and the origins of the social issues Committee of the American Society of Human Genetics, 1964 Genetics, -1973 . Journal of the History of Biology, 50, . Authors also sometimes shortly comment that if sufficient evidence should be provided that points out how the costs and benefits of NBS should be balanced to all alternative ways to spend money on health care for children, we would never have preventive programs as providing this evidence would be too complex and time-consuming. In discussions about the purpose of NBS, human rights function as a way to legitimize the selection of some diseases in the program, and oppose the inclusion of others. impacts. Discussions about the desirability of the return of various types of disease information feature primarily consequentialist language, as NBS promotes human welfare and is therefore outcomeoriented (in terms of 'benefits' and 'harms').
The disagreement is about how these 'benefits' or 'harms' should be understood, whose benefits should be taken into account and how much benefit NBS should produce. In the following, we will distinguish different ways in which NBS influences lives by using the terms 'hard' and 'soft' impacts from philosophy of technology. 'Hard' impacts are typically quantifiable in terms of number of affected children or life years gained and constitute the most broadly accepted focus of NBS; 'soft' impacts refer to psychosocial impacts that influence the experienced quality of life and need to be described in qualitative terms. 26 The question whether and to what extent NBS is allowed to produce soft impacts is much more controversial, as this concerns people's private lives and does not fit within the presupposed liberal constraints.
Hard impacts
Health is a 'hard impact' of NBS and is the least controversial value in the ethical debate on NBS. risk and late-onset diseases, described below, authors such as Ross advise against disclosure if there is no prevention strategy. 41 
Soft impacts
Soft impacts are hotly debated and refer to outcomes of NBS that influence human socio-emotional wellbeing, such as psychosocial harms or benefits that families may experience when they receive information about risks, late(r)-onset diseases, or carrier status information. Benefits include a sense of relief to know that a particular child did not inherit a family disease, or empowerment of parents to make their own decisions about their future reproduction when they receive this information. 42 Disclosure of information about late(r)-onset or untreatable diseases also helps avoiding the so-called 'diagnostic odyssey'; a long and burdensome search for a diagnosis, which children with rare diseases often undergo because physicians have difficulty recognizing the symptoms and requesting the appropriate diagnostic texts. 43 Having a diagnosis of untreatable diseases has intrinsic importance, according to Botkin and Rothwell, who refer to empirical studies that suggest it helps parents to move toward acceptance of the disease and organize their lives around it. 44 Others are more critical of this soft benefit, arguing that shortening the diagnostic odyssey should not be the task of NBS; it can also be shortened if pediatricians' ability to recognize these diseases is improved.
45
Many authors also expect soft harms from the disclosure of untreatable diseases, late(r)-onset diseases, risk information and carrier status, as their disclosure can produce parental feelings of anxiety, stress and guilt, resulting in disrupted parent-child bonding, overprotection, damage to the child's self-esteem, and diminished wellbeing. Expected social harms include stigmatization or discrimination within the family or in society, which may lead to difficulties to form relationships later in life, make reproductive decisions, obtain insurance, buy a house, or find a job. 46 An issue particular to adult-onset diseases or risk information is medicalization of the healthy life of a child, or the creation of 'patients in waiting': people diagnosed with a disorder and 'waiting' for its symptoms to develop. 47 As children 'at risk' may be treated differently by parents, they can develop disordered illness behavior later in life such as excessive worries about health. 48 The Characterizing soft impacts as personal or family values allows to appreciate NBS' influence on people's private lives and raise the question how this influence ought to be shaped and limited. Most authors however say that parents should decide about soft impacts privately.
Considerations about parental duties are rare, as well as calls to involve a broad variety of stakeholders-including clinicians, researchers, ethicists, public health professionals, policymakers, and patients-in thinking about what/whose benefits should be the focus of NBS 57 or that the public of parents at large should be involved in establishing the goals of NBS policy. Table 2 ). Unexpected findings have been part of NBS since the beginning, but attract more attention at the prospect of introducing NGS in NBS, as this may lead to an increase in the number and variety of results not included in the program.
Insofar as these findings reveal untreatable variants of diseases, late (r)-onset diseases, risk information or carrier status, the issues addressed in the literature largely mimic the hard and soft benefits and harms brought forward in the previous section. 59 Uncertain findings, however, raise a slightly different set of problems, as a lack of knowledge about prognosis or effects of treatment makes adequate counseling difficult.
60
NBS may produce all kinds of information of unknown clinical significance as a by-product, especially once NGS is introduced. 61 Such findings do not clearly indicate that a child is diseased, nor that the child is healthy, thus complicating treatment decisions. 62 Treating the child as diseased may lead to harmful overtreatment, it can produce aforementioned psychosocial effects and adversely impact access to life-saving and costly medical interventions, such as heart or lung transplants. 63 But treating children as healthy comes with the risk of the child developing symptoms which early treatment could probably have prevented. 64 Additionally, some authors claim that results that are not included in the program may negatively impact parents' trust in NBS, as they do not anticipate these findings and may not want them. 65 Consequently they may refuse to subject their next child to screening, which would make NBS less effective in detecting affected children. Trust in NBS is therefore considered fragile in view of results that do not fit the NBS program, as they influence the private lives of people inadvertently. proposes adopting an opt-out procedure for treatable diseases, allowing parents the possibility to choose while also nudging them toward consent, and an opt-in or more formal consent process for other conditions. 78 The advantage of such an approach would be that information is needed for both tiers and parental autonomy is respected, but in tier two more information needs to be offered to support parental consent.
| The manner in which the public is involved

Disadvantages are that new knowledge about diseases included in NBS
necessitates a continuous revision of the two tiers. Furthermore, screening for tier one diseases may occasionally identify diseases belonging to tier two, and healthcare professionals need to be welleducated about NBS to explain to parents the difference between both tiers. 
| Difficulties in voluntary programs
In voluntary programs, expansions of the NBS panel increases the complexity and volume of information that needs to be provided to parents. 80 Informing is difficult for it needs to be done in a limited time, yet should be sufficient, and avoid being alarmist about diseases that will occur very rarely. 81 Information should be given when parents are 68 receptive to it, by knowledgeable healthcare providers who are able to attune information to the socio-cultural context of parents. 82 However, many authors warn that healthcare professionals may not inform parents well when NBS expands, as they lack knowledge about the rare diseases included in NBS, and the results that are not aimed for by the program, making it difficult to enable parents to give truly informed consent. 83 Parents, on the other hand, may be unable to grasp the information provided and their eventual consent may be perfunctory. 84 The introduction of genetic technologies will only increase these perceived problems of giving and receiving information. 85 To avoid an information overload for parents, authors discuss the type of informed consent procedure that should be adopted. Formal informed consent procedures require giving extensive information and asking for a signature from parents; more informal informed consent procedures allow informing parents in more general terms and giving them the chance to opt-out. 86 Some argue that generic consent suffices when NBS serves the health of babies, 87 others suggest parents should be offered the possibility to choose from a more differentiated 'menu of options' about which they need to be informed more extensively. 88 What model of informed consent is adopted depends, however, on the purpose of the program and its expected acceptance by society as well as on the potential findings that are not aimed for by the program. Some authors fear that these findings are detrimental to parental trust in NBS. 89 Others focusing on this problem of 'incidental'
or 'unsolicited' findings, suggest that trust can be preserved if consent is asked for the disclosure of these findings too. 90 Authors opposing this idea argue that NBS should serve the infant's health; especially disclosure of incidental findings that are relevant to other family members is problematic as it infringes the right not to know of these family members. 91 Another group of authors suggests making a distinction between different kinds of information: they say, for example, that only incidental genetic variants which point to serious and actionable health problems should be disclosed. 92 In all these reflections, however, what is negotiated is how the personal and private choice of parents about their use of NBS for the care of their children ought to be fostered by means of information, even if NBS offers them an abundance of (sometimes unexpected) results.
| CON CL U SION AN D D IS CU SSION
Our analysis of the literature yields an overview of the issues and values that play a role in the discussion, which we presented in Table 3 .
The most striking result of our analysis is that anticipated expansions of the NBS program beyond its original focus on health improvement for children, lead to more calls to make participation in NBS (at least In our view, soft impacts caused by NBS deserve more attention in ethical reflection, as they offer possibilities whose value for the care of children should be taken into account. One of the ways to achieve this is by means of fostering a dialogue in which parents of healthy and dis- NBS, but we listed the questions that we think are a valuable starting point for its development in Table 4 . These questions invite empirical research and theoretical reflection on the meaning and normative content of concepts such as care, trust, and solidarity in the context of an expanding NBS program, as well as on whether and how NBS policy can continue to respect the distinction between the public and private domain. This work would enhance the debate about NBS, which is nowadays hampered by the liberal choice to delegate the responsibility for very difficult issues to parents in the private domain.
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